Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients

Melanoma Research

Volumn 24, Issue 4, 2014, Pages 295-304

  Mirjacic Martinovic, Katarina M ^a   Babović, Nada Lj ^a   Džodić, Radan R ^a,b   Jurišić, Vladimir B ^c   Tanić, Nikola T ^b   Konjević, Gordana M ^a,b  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c University of Kragujevac Medical Faculty   (Serbia)

Author keywords

cytotoxicity; DNAM 1; interferon c production; metastatic melanoma; natural killer cells; NKG2D; NKp46; perforin; STAT 1

Indexed keywords

CHROMIUM; DNAX ACCESSORY MOLECULE 1; GAMMA INTERFERON; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12 RECEPTOR BETA2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MEMBRANE RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; STAT1 PROTEIN; UNCLASSIFIED DRUG; CD226 ANTIGEN; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; NCR1 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN; T LYMPHOCYTE ANTIGEN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DEGRANULATION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; MALE; METASTATIC MELANOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; IMMUNOLOGY; MELANOMA; METABOLISM; MIDDLE AGED; PROGNOSIS;

ADULT; AGED; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; FEMALE; HUMANS; KILLER CELLS, NATURAL; MALE; MELANOMA; MIDDLE AGED; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PERFORIN; PROGNOSIS; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS;

EID: 84904036773     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000072     Document Type: Article

References (43)

1. Fong ZV, Tanabe KK. Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol 2014; 170:20-30.
2. Langers I, Renoux VM, Thiry M, Delvenne P, Jacobs N. Natural killer cells: role in local tumor growth and metastasis. Biologics 2012; 6:73-82.
3. Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol 2013; 132:536-544.
4. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294: 15-22.
5. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013; 368:161-170.
6. Konjevic G, Radenkovic S, Srdic T, Jurisic V, Lj Stamatovic, Milovic M. Association of decreased NK cell activity and IFNg expression with pSTAT dysregulation in breast cancer patients. J BUON 2011; 16: 219-226.
7. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-640.
8. Bé ziat V, Descours B, Parizot C, Debré P, Vieillard V. NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS One 2010; 5:e11966.
9. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502.
10. Zafirova B, Wensveen FM, Gulin M, Polić B. Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci 2011; 68:3519-3529.
11. El-Gazzar A, Groh V, Spies T. Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J Immunol 2013; 191:1509-1515.
12. Brusilovsky M, Rosental B, Shemesh A, Appel MY, Porgador A. Human NK cell recognition of target cells in the prism of natural cytotoxicity receptors and their ligands. J Immunotoxicol 2012; 9:267-274.
13. De Andrade LF, Smyth MJ, Martinet L. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol Cell Biol 2014; 92:237-244.
14. Rajalingam R. Overview of the killer cell immunoglobulin-like receptor system. Methods Mol Biol 2012; 882:391-414.
15. Abeyweera TP, Merino E, Huse M. Inhibitory signaling blocks activating receptor clustering and induces cytoskeletal retraction in natural killer cells. J Cell Biol 2011; 192:675-690.
16. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206.
17. Brown RL, Ortaldo JR, Griffith RL, Blanca I, Rabin H. The proliferation and function of human mononuclear leukocytes and natural killer cells in serumfree medium. J Immunol Methods 1985; 81:207-214.
18. Jackson A, Warner N. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose N, Friedmah H, Fahey J, editors. Manual of clinical laboratory immunology. 3rd ed. Washington, DC: American Society for Microbiology; 1986. pp. 226-235.
19. Konjević G, Mirjacić Martinović K, Jurisić V, Babović N, Spuzić I. Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16 + NK cells. Biomarkers 2009; 14:258-270.
20. Mirjacić Martinović K, Konjević G, Babović N, Inić M. The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients. J Surg Res 2011; 171:637-649.
21. SibbittWL Jr, Bankhurst AD, Jumonville AJ, Saiki JH, Saiers JH, Doberneck RC. Defects in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma. Cancer Res 1984; 44: 852-856.
22. Balsamo M, Scordamaglia F, Pietra G, Manzini C, Cantoni C, Boitano M, et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci USA 2009; 106: 20847-20852.
23. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012; 72:1407-1415.
24. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NKcell cytokine and chemokine production by target cell recognition. Blood 2010; 115:2167-2176.
25. De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16 + NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci USA 2011; 108:728-732.
26. Voskoboinik I, Dunstone MA, Baran K, Whisstock JC, Trapani JA. Perforin:structure, function, and role in human immunopathology. Immunol Rev 2010; 235:35-54.
27. Trapani JA, Thia KY, Andrews M, Davis ID, Gedye C, Parente P, et al. Human perforin mutations and susceptibility to multiple primary cancers. Oncoimmunology 2013; 2:e24185.
28. Krzewski K, Gil-Krzewska A, Nguyen V, Peruzzi G, Coligan JE. LAMP1/CD107a is required for efficient perforin delivery to lytic granules and NK-cell cytotoxicity. Blood 2013; 121:4672-4683.
29. Pipkin ME, Rao A, Lichtenheld MG. The transcriptional control of the perforin locus. Immunol Rev 2010; 235:55-72.
30. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol 2012; 13:722-728.
31. Airoldi I, Di Carlo E, Cocco C, Sorrentino C, Fais F, Cilli M, et al. Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood 2005; 106:3846-3853.
32. Cárdenes M, Angel-Moreno A, Fieschi C, Sologuren I, Colino E, Molinés A, et al. Oesophageal squamous cell carcinoma in a young adult with IL-12R beta 1 deficiency. J Med Genet 2010; 47:635-637.
33. Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NKcell function. Blood 2006; 108:4118-4125.
34. Morgado S, Sanchez-Correa B, Casado JG, Duran E, Gayoso I, Labella F, et al. NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions. J Innate Immun 2011; 3:365-373.
35. Glasner A, Ghadially H, Gur C, Stanietsky N, Tsukerman P, Enk J, et al. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J Immunol 2012; 188:2509-2515.
36. Fregni G, Perier A, Pittari G, Jacobelli S, Sastre X, Gervois N, et al. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy. Clin Cancer Res 2011; 17:2628-2637.
37. Fregni G, Messaoudene M, Fourmentraux-Neves E, Mazouz-Dorval S, Chanal J, Maubec E, et al. Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. PLoS One 2013; 8:e76928.
38. Baginska J, Viry E, Paggetti J, Medves S, Berchem G, Moussay E, et al. The critical role of the tumor microenvironment in shaping natural killer cellmediated anti-tumor immunity. Front Immunol 2013; 4:490.
39. Messaoudene M, Fregni G, Fourmentraux-Neves E, Chanal J, Maubec E, Mazouz-Dorval S, et al. Mature cytotoxic CD56bright/CD16 + natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res 2014; 74:81-92.
40. Montaldo E, Del Zotto G, Della Chiesa M, Mingari MC, Moretta A, De Maria A, et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry A 2013; 83:702-713.
41. Allan DS, Rybalov B, Awong G, Zún iga-Pflü cker JC, Kopcow HD, Carlyle JR, et al. TGF-b affects development and differentiation of human natural killer cell subsets. Eur J Immunol 2010; 40:2289-2295.
42. Domaica CI, Fuertes MB, Uriarte I, Girart MV, Sardanons J, Comas DI, et al. Human natural killer cell maturation defect supports in vivo CD56(bright) to CD56(dim) lineage development. PLoS One 2012; 7:e5167.
43. Peng YP, Zhu Y, Zhang JJ, Xu ZK, Qian ZY, Dai CC, et al. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med 2013; 11:262.